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Abstract: Aerosols delivered by Respimat® Soft Mist™ Inhaler (SMI) are slower-moving 
and longer-lasting than those from pressurized metered-dose inhalers (pMDIs), improving the 
efﬁ  ciency of pulmonary drug delivery to patients. In this four-way cross-over study, adults 
with chronic obstructive pulmonary disease (COPD) and with poor pMDI technique received 
radiolabelled Berodual® (fenoterol hydrobromide 50 μg/ipratropium bromide 20 μg) via 
Respimat® SMI or hydroﬂ  uoroalkane (HFA)-MDI (randomized order) on test days 1 and 2, with 
no inhaler technique training. The procedure was repeated on test days 3 and 4 after training. 
Deposition was measured by gamma scintigraphy. All 13 patients entered (9 males, mean age 
62 years; FEV1 46% of predicted) inhaled too fast at screening (peak inspiratory ﬂ  ow rate [IF]: 
69–161 L/min). Whole lung deposition was higher with Respimat® SMI than with pMDI for 
untrained (37% of delivered dose vs 21% of metered dose) and trained patients (53% of delivered 
vs 21% of metered dose) (pSign-Test = 0.15; pANOVA  0.05). Training also improved inhalation 
proﬁ  les (slower average and peak IF as well as longer breath-hold time). Drug delivery to the 
lungs with Respimat® SMI is more efﬁ  cient than with pMDI, even with poor inhaler technique. 
Teaching patients to hold their breath as well as to inhale slowly and deeply increased further 
lung deposition using Respimat® SMI.
Keywords: chronic obstructive pulmonary disease, drug delivery, inhalation, metered-dose 
inhaler, poor inhalation technique, training
Introduction
Ever since pressurized metered-dose inhalers (pMDIs) were introduced in 1956, 
patients have had difﬁ  culty in using them correctly (Epstein et al 1979; Crompton 1982; 
Molimard et al 2003). Mistakes are made in preparation, such as failing to remove the 
dust cap or, in the case of chloroﬂ  uorocarbon (CFC)-propelled MDIs, not shaking the 
inhaler. A common error is that the inhaler is ﬁ  red before inhalation begins or after it 
ends (McFadden 1995; Newman 2005). In asthma patients, incorrect use of  pMDIs 
has been shown to reduce the efﬁ  cacy of an inhaled bronchodilator (Lindgren et al 
1987) and was associated with poorer disease control, particularly in patients who did 
not correctly co-ordinate inhaler ﬁ  ring and inhalation (Giraud and Roche 2002).
A feature of pMDIs that makes co-ordination difﬁ  cult is the rapid speed at which 
they deliver the aerosol cloud, which may only last for 0.15 sec for CFC-MDIs, 
although aerosol clouds from the newer hydroﬂ  uoroalkane (HFA)-propelled MDIs 
last for up to 0.36 sec (Hochrainer et al 2005). The Respimat® Soft Mist™ Inhaler 
(SMI), a propellant-free metered-dose inhaler, delivers aerosols that are slower-moving 
and last 4–10 times longer than aerosols from pMDIs (Hochrainer et al 2005). This is 
an innovation that has been shown to deliver a higher proportion of the emitted dose to 
the lungs than with CFC-MDIs with and without spacer in healthy subjects (Newman 
et al 1996, 1998). This enables the nominal dose of bronchodilator to be reduced at least International Journal of COPD 2008:3(4) 764
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2-fold while maintaining efﬁ  cacy and safety in patients with 
chronic obstructive pulmonary disease (COPD) and asthma 
(Kilfeather et al 2004; von Berg et al 2004).
Teaching the correct inhaler technique was shown to 
improve drug delivery and bronchodilator response in asthma 
patients using a CFC-MDI (Newman et al 1991). The purpose 
of our study was to compare the efﬁ  ciency of lung deposition 
in patients with COPD using Respimat® SMI and a pMDI. By 
selecting patients with a poor inhaler technique and including 
a training step, the inﬂ  uence of inhaler technique on lung 
deposition was assessed.
Methods
Study design
This lung deposition study employed a four-way cross-over 
design, and was randomized with regard to drug dosing 
sequence. It was done at a single investigative centre in 
Germany (Inamed Research, Gauting, Germany), where 
patients with doctor-diagnosed COPD were recruited for 
screening visit followed by four test days at least two days 
(but no more than 14 days) apart.
The study protocol complied with German federal drug laws, 
met radiation protection requirements and was conducted in 
compliance with the Declaration of Helsinki and Good Clinical 
Practice. Local and federal ethics approval was obtained and all 
patients gave written informed consent for participation.
Patients
To be eligible for entry to the study, adults aged at least 40 years 
with doctor-diagnosed COPD, a forced expiratory volume in 
1 second (FEV1) of no more than 65% of predicted, a ratio of 
FEV1 to forced vital capacity (FVC) of no more than 0.70 and 
who were current or former smokers (at least 10 pack years) had 
to show a poor pMDI technique. This was deﬁ  ned as at least 
one of the following inhalation errors, based on descriptions of 
the ideal technique in the published literature (Newman et al 
1980, 1981; Dolovich et al 1981): failure to co-ordinate ﬁ  ring 
of a pMDI with inhalation (those who pressed the button less 
than 0.2 sec before inhalation but did inhale more than 1 L in 
volume actuation); an average inspiratory ﬂ  ow (IF) of at least 
40 L/min and a peak IF of at least 60 L/min; and reporting by 
the patient of a “cold freon” effect, where the patient abruptly 
stops inhaling because of the uncomfortable feeling of the 
aerosol spray hitting the back of the throat.
Interventions
Within 21 days of the screening visit, eligible patients 
attended the study centre for the ﬁ  rst of four test days. On 
each test day, patients received a single dose of  99mTechnetium 
(Tc)-radiolabeled Berodual® (fenoterol hydrobromide 50 μg/
ipratropium bromide 20 μg per actuation) via either Respimat® 
SMI (1 actuation of 50/20 μg) or HFA-MDI (2 actuations of 
50/20 μg each). All test doses were open-label; no blinding 
procedure was used. For both inhalers, the dose of radiolabel 
in one actuation was calculated such that the total amount of 
radioactivity administered on each test day would not exceed 
4 MBq (although this limit was exceeded for 3 patients; see 
below). For both test inhalers, the radiolabeled formulations 
were tested in vitro to ensure that the particle size distribution 
was equivalent to that of an unlabelled product.
On each test day, the ﬁ  ne particle dose of radiolabelled 
product was 14%–32% of the mean radioactive output 
from HFA-MDI and 50%–80% from Respimat® SMI, as 
measured by gamma counts on the appropriate stages of an 
Andersen cascade impactor (Shibata Scientiﬁ  c Technology 
Ltd., Japan), as well as by chemical assay.
On test days 1 and 2, patients inhaled with Respimat® 
SMI or HFA-MDI using their usual technique, ie, no inhaler 
training was given. On test days 3 and 4, patients received 
instruction by a technician, physician or study nurse on the 
correct use of the test inhaler according to the instructions 
of the manufacturers, and were given time to practice with 
a placebo formulation before they inhaled any study drug. 
They were taught to inhale slowly and deeply from residual 
volume and to hold their breath for at least 10 sec. When 
patients could perform the inhalation technique correctly at 
a target rate of 30 L/min, the placebo was replaced with the 
radiolabelled formulation. The sequence in which a patient 
received Respimat® SMI or HFA-MDI on the “untrained” and 
“trained” test days was randomly allocated at the start of test 
day 1. The four possible sequences are shown in Table 1.
Assessments
Before each patient used an inhaler on any of the test days, 
3 actuations (puffs) were ﬁ  red onto 3 separate inhalation ﬁ  lters, 
to ensure that the output of the inhaler was constant. To mini-
mize contamination of the test environment, the patients used 
a nose clip for all test inhalations and all post-dose exhalations 
were made through a ﬁ  lter. A ﬂ  ow meter was used to record the 
inhalation proﬁ  le over time (inhalation duration and volume, 
average and peak inhaled ﬂ  ow rate, and duration of breath 
hold). Calibration curves were deﬁ  ned using tube ﬁ  ttings which 
were adapted for each investigated device. The ﬂ  ow proﬁ  les 
were derived from pressure values of each test trial considering 
these device-depending calibration curves. These proﬁ  les were 
recorded on an inhalation trace (example shown in Figure 1). 
This showed the time points when inhalation started and when International Journal of COPD 2008:3(4) 765
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the inhaler was ﬁ  red, and allowed lag time between these 
two events to be recorded. The breath-hold duration was also 
measured by an observer with a stopwatch.
Immediately after dosing, lung radiograms were taken to 
measure deposition of radiolabel by gamma scintigraphy using 
a Siemens Diacam gamma camera. For imaging, patients sat 
upright with their backs to the camera (posterior view), and 
a sequence of images was collected over a 30-second period. 
Radioactivity on the inhalation and exhalation ﬁ  lters and 
mouthpiece was measured with a scintillation counter. The 
mean of the radioactivity on the three ﬁ  lters was taken as the 
total emitted activity from each inhaler; deposited activity 
was derived by subtracting the activity of exhalation ﬁ  lters 
from the emitted activity (as mean of the results of the three 
ﬁ  lters) (Phipps et al 1989; Snell and Ganderton 1999).
To determine the regional distribution of radioactivity, all 
regions of interest were delineated on each radiogram using 
lung outlines from a posterior krypton (81mKr) ventilation 
scan performed on each patient on one of the four test days. 
This scan was used to deﬁ  ne the edges of the lung ﬁ  elds and 
further subdivision into central, intermediate and peripheral 
regions. The remaining regions deﬁ  ned the oropharynx, 
esophagus, and stomach. Counts in all regions were corrected 
for background radiation count, radioactive decay, and for 
the effect of attenuation of gamma rays by overlying tissue 
(Pitcairn and Newman 1997).
Endpoints and statistical analysis
The primary endpoint was whole lung deposition, ie, the 
proportion of the dose deposited in whole lung expressed as a 
fraction (%) of the delivered dose (ex-mouthpiece) for  Respi-
mat® SMI and of the metered dose for HFA-MDI. Secondary 
endpoints were the deposition of radiolabel in 3 lung regions 
(central, intermediate, and peripheral) and in the oropharynx. 
Table 1 Allocation of test inhaler on each of the four test days
Usual technique (before training) Technique after training
Test day 1 2 3 4
Sequence 1 Respimat® SMI HFA-MDI Respimat® SMI HFA-MDI
Sequence 2 Respimat® SMI HFA-MDI HFA-MDI Respimat® SMI
Sequence 3 HFA-MDI Respimat® SMI HFA-MDI Respimat® SMI
Sequence 4 HFA-MDI Respimat® SMI Respimat® SMI HFA-MDI
Abbreviations: HFA-MDI, hydroﬂ  uoroalkane-metered-dose inhaler; SMI, Soft Mist™ Inhaler.
Inhalation and release time
Start of inhalation
Flow (L/min)
to press the button
Time (s)
Duration of Inhalation (s)
PIFR (L/min)
Release time point (s)
Actual inhaled Flow rate (L/min)
Inhaled Volume (L) Starting time  5.72    0.00
Time of end  9.74    0.00
Release time  6.13    6.00
End of inhalation
4.0
42
0.4
29
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Figure 1 Inspiratory ﬂ  ow proﬁ  le during inhalation from Respimat® Soft Mist™ Inhaler (using trained technique). Courtesy Inamed Research.International Journal of COPD 2008:3(4) 766
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The ratio of peripheral deposition to central deposition 
(penetration index [PI]) was calculated and normalized to the 
ratio calculated from the krypton scans as a measure of the topo-
graphical distribution of the deposited aerosol in the lungs.
Deposition data were analyzed for all patients who 
completed all four test days (the full analysis set). Statistical 
analysis of the primary endpoint was done using the Sign test, 
a non-parametric test. The null hypothesis tested was that there 
is no difference between Respimat® SMI and HFA-MDI with 
respect to the improvement in whole lung deposition achieved 
after training compared with that achieved with the patient’s 
untrained technique. For each patient, the following sum was 
calculated and its sign (negative or positive) noted:
([Deposition from Respimat, untrained] ÷ [Deposition 
from Respimat, trained]) − ([Deposition from HFA-MDI, 
untrained] ÷ [Deposition from HFA-MDI, trained]).
If this sum (median value for all patients) was positive, it 
would indicate that training was more effective for HFA-MDI, 
and if negative, it would indicate that training was more effec-
tive for Respimat® SMI. To assess the statistical signiﬁ  cance 
of the difference between inhalers, the number of positive and 
negative differences between them were compared with those of 
a binomial distribution (in which the probabilities of a positive 
and a negative difference are the same, ie, 50% each). Statistical 
signiﬁ  cance was assessed at the two-sided 5% level.
An additional supportive analysis was done using analysis of 
variance (ANOVA), for which whole lung deposition data were 
transformed logarithmically before use. The same mathematical 
construct was used as for the Sign test except that for each inhaler, 
the trained value was subtracted from the untrained value. Sta-
tistical analysis of the results was done using the SAS software 
(version 9.1, SAS Institute Inc, Cary, North Carolina, USA).
Results
The characteristics at screening of the 13 patients who entered 
the study are shown in Table 2. Inhaler technique assessment at 
the screening visit showed that all 13 patients inhaled too fast 
(inspiratory ﬂ  ow of 26–105 L/min [average] and 69–161 L/min 
[peak]). None showed poor co-ordination of inhaler ﬁ  ring, the 
lag time between inhalation start and inhaler ﬁ  ring ranging 
from –0.1 to +0.4 sec. None reported “cold freon” effect.
One patient did not complete the study because of an 
acute COPD exacerbation that was judged not to be related 
to study medication. Therefore, the full analysis set consisted 
of 12 patients.
In 3 patients, the radioactivity inhaled in 1 actuation was more 
than the intended maximum of 4 MBq (4.1, 4.4, and 4.5 MBq). 
The Radiological Protection Board was notiﬁ  ed of this.
Inhalation technique
The instruction in correct inhaler technique for the two inhalers 
on test days 3 and 4 produced appropriate improvements in key 
attributes of technique for both test inhalers. The mean average 
and peak IF rates were numerically slower, the mean duration 
of the inspiratory breath was numerically longer, and the mean 
breath-hold increased to more than 10 sec (Table 3).
Deposition proﬁ  les
When patients used their own (poor) technique, there was 
trend towards higher values of mean whole lung deposi-
tion with Respimat® SMI (37% of delivered dose, standard 
Table 2 Characteristics of 13 COPD patients at screening
Mean value (standard deviation)
Age, year 61.6 (4.9)
Men/women, n 9/4
Ex-smokers/smokers, n 5/8
Smoking history, pack years 46.9 (20.3)
FEV1, L 1.37 (0.49)
FEV1, % of predicted 46.4 (14.4)
FEV1/FVC, ratio 0.44 (0.09)
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 3 Characteristics of inhalation technique before and after training with both inhalers studied.   Values are mean (standard deviation 
in parentheses) for full analysis set (n = 12)
Respimat® SMI pMDI
Untrained Trained Untrained Trained
Duration of inhalation, s 1.56 (0.52) 4.04 (1.17) 2.00 (0.45) 4.34 (0.92)
Inhaler ﬁ  ring lag time, s 0.03 (0.16) 0.00 (0.23) 0.07 (0.23) 0.12 (0.27)
Inhaled volume, L 2.13 (0.85) 2.32 (0.90) 2.21 (0.76) 2.24 (0.53)
Mean inspiratory ﬂ  ow rate, L/min 86.6 (33.1) 35.2 (10.6) 68.9 (23.4) 33.2 (10.0)
Peak inspiratory ﬂ  ow rate, L/min 146.9 (44.5) 67.9 (24.2) 112.7 (32.0) 55.9 (10.0)
Duration of breath hold, s 8.3 (4.0) 10.5 (1.2) 8.6 (4.5) 11.0 (0.6)
Abbreviations: pMDI, pressurized metered-dose inhaler; SMI, Soft Mist™ Inhaler.International Journal of COPD 2008:3(4) 767
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deviation [SD] 14%) than with HFA-MDI (21% of metered 
dose, SD 7%). After training, the mean value for Respimat® 
SMI increased further to 53% of delivered dose (SD 17%), 
but the value for HFA-MDI was virtually unchanged (21% 
of metered dose, SD 10%) (Figure 2a). Analysis of the dif-
ference between inhalers by Sign test showed that more of 
the differences were negative than positive, suggesting that 
training had been more effective for Respimat® SMI. How-
ever, the difference was not signiﬁ  cant (median value –0.38; 
pSign test = 0.15). An ANOVA veriﬁ  ed same direction of 
difference, but resulted in a statistically signiﬁ  cant dif-
ference (pANOVA   0.05). In a similar pattern to the whole 
deposition results, mean oropharyngeal deposition from 
Respimat® SMI was reduced by training (56% of delivered 
dose before to 45% of delivered dose after it), but the mean 
value for HFA-MDI after training (56% of metered dose) 
was very similar to that before training (55% of metered 
dose; Figure 2b).
For both inhalers, the distribution of deposited aerosol 
in different lung regions after training showed few changes 
(Table 4). With Respimat® SMI, the mean deposition 
values in all three lung regions were numerically higher 
after training than before, but distributed in a very similar 
proportion to the pre-training results. With HFA-MDI, the 
deposition values were unchanged after training. Conse-
quently, the changes in PI for both inhalers were small and 
of no clinical relevance.
Samples of scintigraphy images after inhalation with 
Respimat® SMI and HFA-MDI before and after technique 
training are shown in Figure 3.
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Figure 2 Mean deposition values (as % of delivered dose for Respimat® Soft Mist™ Inhaler and % of metered dose for pMDI) from the two inhalers before and after training 
(standard deviation shown as error bar):  a) whole lung deposition, b) oropharyngeal deposition.International Journal of COPD 2008:3(4) 768
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Table 4 Mean deposition (standard deviation in parentheses) [% of delivered dose for Respimat® SMI and % of metered dose for pMDI] 
of radiolabel in the three lung regions in full analysis set (n = 12)
Lung region Penetration indexa
Central Intermediate Peripheral
Respimat® SMI: untrained 17.9 (10.0) 11.7 (3.9) 7.80 (2.3) 0.50 (0.20)
Respimat® SMI: trained 25.0 (9.9) 17.7 (6.1) 9.9 (3.4) 0.45 (0.20)
pMDI: untrained 11.1 (5.0) 6.1 (2.3) 3.6 (1.2) 0.39 (0.19)
pMDI: trained 11.0 (6.6) 6.5 (2.7) 3.8 (1.8) 0.44 (0.21)
aRatio of peripheral to central deposition.
Abbreviations: pMDI, pressurized metered-dose inhaler; SMI, Soft Mist™ Inhaler.
Discussion
Mean deposition of a combination bronchodilator in whole 
lung from Respimat® SMI was about twice that from 
HFA-MDI after patients were trained in the optimal use of 
both inhalers. The deposition for Respimat® SMI was mea-
sured as percent of delivered dose contrary to the deposition 
of HFA-MDI measured as percent of metered dose; these are 
the declared doses for the two marketed products.
The improvement in deposition after training in this 
study was not statistically significant according to the 
prospectively deﬁ  ned analysis (Sign test). The direction of 
difference, however, indicated a greater effect of training 
with Respimat® SMI (3 patients had a greater training effect 
with HFA-MDI and 9 with Respimat), and analysis of the 
same data using an alternative prospectively deﬁ  ned test 
(ANOVA) did show a signiﬁ  cantly greater effect of training 
with Respimat® SMI.
These ﬁ  ndings suggest that training patients in correct 
inhaler technique is beneﬁ  cial for Respimat® SMI, not-
withstanding the good deposition results achieved before 
training. The lack of improvement after training with pMDI, 
however, contrasts with the ﬁ  ndings of other studies (Kemp 
and Meltzer 1990; Newman et al 1991; Minai et al 2004). 
The reason for this may be that although all of the patients 
in our study were judged as having a poor technique, the 
error they committed was to inhale too quickly – none 
showed poor co-ordination of inhaler ﬁ  ring with inhalation. 
In asthma patients using CFC-MDIs, delivery was markedly 
improved after training in poor co-ordinators but not in those 
who were judged as good coordinators (Newman et al 1991). 
Poor co-ordination might therefore be a more crucial error 
of technique with pMDIs than inhaling too fast – asthma 
control was found to be worse in asthma patients who 
misused pMDIs than in those with good technique, and the 
worst level of control was in poor coordinators (Giraud and 
Roche 2002).
The mean lung deposition values recorded with both 
inhalers in our study are higher than those of two studies in 
healthy non-smoking volunteers who were trained in optimal 
inhalation technique for the ﬁ  nal prototype of Respimat® 
SMI and a CFC-MDI. Mean whole lung deposition from 
Respimat® SMI was 39% for an aqueous solution of fenoterol, 
11% from CFC-MDI used without a spacer and 10% from 
CFC-MDI used with an AeroChamber spacer (Newman et al 
1998). When comparing these results, however, account must 
be taken of the different methods for expressing the delivered 
dose from Respimat® SMI. In our study, this was expressed 
as the dose that leaves the mouthpiece (which is the declared 
dose for the product), whereas in the earlier study, it was 
expressed as the dose leaving the nozzle, ie, including an 
amount deposited on the mouthpiece; restating the results of 
the earlier study using ex-mouthpiece doses would produce 
slightly higher values, reducing the discrepancy between the 
two studies. Observation of Newman et al with CFC-MDIs 
resulted in similar distribution as we have shown in this 
investigation (mean whole lung deposition in healthy subjects 
of 26% of metered dose (SD 6%) versus mean whole lung 
deposition in patients with COPD before training of 21% of 
metered dose (7%) and after training of 21% of metered dose 
(10%) (Newman et al 1998). These ﬁ  ndings are consistent 
with ﬁ  ndings of other studies in volunteers and in patients 
with asthma or COPD (Leach et al 2002; Häussermann et al 
2007) probably because HFA-MDIs have a higher fraction 
of ﬁ  ne particles that are more easily respirable, and because 
these are emitted at a lower velocity.
The measurements of inspiratory performance in our 
study gave immediate feedback on the degree of success of 
the inhaler technique training, and provided more context 
for the observed deposition performance of the two inhal-
ers. The mean breath-hold duration increased from 9 to over 
10 seconds after training. Average and peak IF were similar 
for both inhalers after training (33–35 L/min), and much International Journal of COPD 2008:3(4) 769
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slower than before training, but although these slower ﬂ  ows 
seemed to improve mean deposition from Respimat® SMI, 
they had no effect on deposition from pMDI. This suggests 
that training patients to inhale more slowly and deeply may 
make little difference to lung delivery in patients using 
pMDI, but will have greater beneﬁ  ts for those using products 
delivered via Respimat® SMI.
Patients who use dry powder inhalers (DPIs) do not have 
the challenge of having to co-ordinate inhalation with inhaler 
ﬁ  ring, and are trained to inhale with a higher peak IF, to 
ensure full de-agglomeration of the powder. A comparison in 
asthma patients showed that deposition of budesonide from 
the Turbuhaler® at a fast peak IF (29%) was higher than at low 
peak IF (18%), but optimal inhalation from Respimat® SMI 
(slow average IF) produced signiﬁ  cantly higher deposition 
(52%) (Pitcairn et al 2005).
A key limitation of our investigation, in common with 
other scintigraphy studies, was the small number of patients, 
which produced a large variability in both deposition results 
and inhalation proﬁ  les as shown by standard deviations around 
our mean estimates. Using larger patient numbers in trials 
involving exposure to ionizing radiation is very difﬁ  cult to jus-
tify. This constraint was mitigated by using a four-way cross-
over design that allowed the widest possible comparative 
analysis from the small sample. Although possible period bias 
was controlled for by randomizing the treatment sequence, 
it was not possible to blind the inhalers to investigators or 
patients because of differences in their geometry, and this 
might have introduced a preference bias.
In summary, drug delivery to the lungs with Respimat® 
SMI was found to be more efﬁ  cient than with HFA-MDI, 
even in patients who have a poor inhaler technique. Inhaler 
Figure 3 Samples of scintigraphic images from a patient showing deposition pattern from Respimat® Soft Mist™ Inhaler before training (a) and after training (b), and from 
pMDI before training (c) and after training (d).International Journal of COPD 2008:3(4) 770
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training further improved the deposition proﬁ  le for Respimat® 
SMI, but made almost no difference to the proﬁ  le for pMDI. 
This is in keeping with clinical trials seen in patients with 
asthma and COPD who were treated at home (without 
supervision) with Berodual® administered from either the 
Respimat® SMI or from a pMDI. These studies showed that 
reducing the dose in the Respimat® SMI to half, or even 
one quarter, of the nominal dose of the pMDI resulted in 
comparable efﬁ  cacy and safety (Kassner et al 2004; Vincken 
2008). Teaching patients to inhale slowly and deeply and 
hold their breath for as long as they can increases further 
lung deposition from Respimat® SMI.
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